Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations.

Journal of diabetes investigation·2022
Same author

The status of diabetes and its complications in Latin-American population: A review article.

Diabetes research and clinical practice·2020
Same author

Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.

Clinical diabetes and endocrinology·2020
Same author

Comment on Riddle et al. <i>Diabetes Care</i> Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care 2019;42:1136-1146.

Diabetes care·2019
Same author

TRANSCULTURAL DIABETES CARE IN THE UNITED STATES - A POSITION STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2019
Same author

SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.

Postgraduate medicine·2019
Same journal

Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures.

Postgraduate medicine·2026
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
Same journal

Operational and demographic predictors of leaving without being seen in a high-volume tertiary emergency department: a five-year case-control study.

Postgraduate medicine·2026
Same journal

Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.

Postgraduate medicine·2026
Same journal

Association between frailty and major chronic disease-free life expectancy: a large community-based longitudinal study.

Postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Initiating insulin therapy.

Jaime A Davidson1

  • 1Endocrine & Diabetes Associates of Texas, Dallas, TX 75230, USA. endodiab@medicalcitydallas.com

Postgraduate Medicine
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Starting insulin therapy for diabetes mellitus (type 1 and type 2) is challenging. Understanding treatment initiation, patient expectations, and novel therapies improves patient outcomes.

More Related Videos

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)

Published on: March 14, 2019

Related Experiment Videos

Last Updated: Jun 21, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)

Published on: March 14, 2019

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Insulin therapy is crucial for managing type 1 and type 2 diabetes mellitus.
  • Initiating insulin treatment presents significant clinical challenges.

Purpose of the Study:

  • To outline key considerations for initiating insulin therapy in diabetes mellitus.
  • To highlight strategies for effective insulin treatment initiation.

Main Methods:

  • Literature review on insulin therapy initiation protocols.
  • Analysis of current guidelines and emerging treatment approaches.

Main Results:

  • Optimal timing and methods for insulin initiation vary by diabetes type.
  • Patient education and expectation management are critical for adherence.
  • Combination therapies offer advanced treatment options.

Conclusions:

  • Effective insulin therapy initiation requires a multifaceted approach.
  • Addressing challenges in treatment initiation improves patient outcomes in diabetes mellitus.